vs
FIDELITY D & D BANCORP INC（FDBC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是FIDELITY D & D BANCORP INC的1.2倍（$30.3M vs $24.4M），FIDELITY D & D BANCORP INC净利率更高（32.5% vs -221.3%，领先253.9%），REGENXBIO Inc.同比增速更快（43.0% vs 15.0%），FIDELITY D & D BANCORP INC自由现金流更多（$24.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 11.8%）
Fidelity D & D Bancorp Inc是一家总部位于美国的地区性银行控股公司，主要在宾夕法尼亚州东北部开展业务，为个人消费者、小微企业及当地社区客户提供存款账户、消费及商业贷款、抵押贷款、财富管理等综合零售及商业银行服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FDBC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$24.4M
营收增速更快
RGNX
高出28.0%
15.0%
净利率更高
FDBC
高出253.9%
-221.3%
自由现金流更多
FDBC
多$77.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
11.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.4M | $30.3M |
| 净利润 | $7.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 37.7% | -190.0% |
| 净利率 | 32.5% | -221.3% |
| 营收同比 | 15.0% | 43.0% |
| 净利润同比 | 36.1% | -31.2% |
| 每股收益（稀释后） | $1.29 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FDBCRGNX
| Q4 25 | $24.4M | $30.3M | ||
| Q3 25 | $23.5M | $29.7M | ||
| Q2 25 | $23.3M | $21.4M | ||
| Q1 25 | $22.0M | $89.0M | ||
| Q4 24 | $21.2M | $21.2M | ||
| Q3 24 | $20.4M | $24.2M | ||
| Q2 24 | $19.7M | $22.3M | ||
| Q1 24 | $19.5M | $15.6M |
净利润FDBCRGNX
| Q4 25 | $7.9M | $-67.1M | ||
| Q3 25 | $7.3M | $-61.9M | ||
| Q2 25 | $6.9M | $-70.9M | ||
| Q1 25 | $6.0M | $6.1M | ||
| Q4 24 | $5.8M | $-51.2M | ||
| Q3 24 | $5.0M | $-59.6M | ||
| Q2 24 | $4.9M | $-53.0M | ||
| Q1 24 | $5.1M | $-63.3M |
毛利率FDBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FDBCRGNX
| Q4 25 | 37.7% | -190.0% | ||
| Q3 25 | 36.5% | -176.3% | ||
| Q2 25 | 35.5% | -296.3% | ||
| Q1 25 | 32.2% | 13.6% | ||
| Q4 24 | 31.4% | -242.1% | ||
| Q3 24 | 28.2% | -256.6% | ||
| Q2 24 | 28.9% | -251.3% | ||
| Q1 24 | 29.5% | -408.8% |
净利率FDBCRGNX
| Q4 25 | 32.5% | -221.3% | ||
| Q3 25 | 31.2% | -208.3% | ||
| Q2 25 | 29.7% | -331.8% | ||
| Q1 25 | 27.2% | 6.8% | ||
| Q4 24 | 27.5% | -241.3% | ||
| Q3 24 | 24.3% | -246.3% | ||
| Q2 24 | 25.0% | -237.7% | ||
| Q1 24 | 25.9% | -405.4% |
每股收益（稀释后）FDBCRGNX
| Q4 25 | $1.29 | $-1.30 | ||
| Q3 25 | $1.27 | $-1.20 | ||
| Q2 25 | $1.27 | $-1.38 | ||
| Q1 25 | $1.03 | $0.12 | ||
| Q4 24 | $1.00 | $-0.99 | ||
| Q3 24 | $0.86 | $-1.17 | ||
| Q2 24 | $0.86 | $-1.05 | ||
| Q1 24 | $0.88 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $148.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $238.9M | $102.7M |
| 总资产 | $2.7B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FDBCRGNX
| Q4 25 | $148.1M | $230.1M | ||
| Q3 25 | $142.2M | $274.2M | ||
| Q2 25 | $165.5M | $323.3M | ||
| Q1 25 | $211.2M | $267.9M | ||
| Q4 24 | $83.4M | $234.7M | ||
| Q3 24 | $120.2M | $255.5M | ||
| Q2 24 | $78.1M | $290.4M | ||
| Q1 24 | $72.7M | $338.7M |
股东权益FDBCRGNX
| Q4 25 | $238.9M | $102.7M | ||
| Q3 25 | $229.2M | $161.5M | ||
| Q2 25 | $217.9M | $213.7M | ||
| Q1 25 | $211.7M | $274.2M | ||
| Q4 24 | $204.0M | $259.7M | ||
| Q3 24 | $207.3M | $301.4M | ||
| Q2 24 | $195.7M | $348.3M | ||
| Q1 24 | $191.6M | $390.7M |
总资产FDBCRGNX
| Q4 25 | $2.7B | $453.0M | ||
| Q3 25 | $2.7B | $525.2M | ||
| Q2 25 | $2.7B | $581.0M | ||
| Q1 25 | $2.7B | $490.9M | ||
| Q4 24 | $2.6B | $466.0M | ||
| Q3 24 | $2.6B | $519.1M | ||
| Q2 24 | $2.5B | $569.4M | ||
| Q1 24 | $2.5B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $42.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $24.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 101.7% | -174.0% |
| 资本支出强度资本支出/营收 | 71.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.34× | — |
| 过去12个月自由现金流最近4个季度 | $45.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FDBCRGNX
| Q4 25 | $42.4M | $-52.3M | ||
| Q3 25 | $8.4M | $-56.0M | ||
| Q2 25 | $12.6M | $-49.3M | ||
| Q1 25 | $11.7M | $33.6M | ||
| Q4 24 | $29.6M | $-31.6M | ||
| Q3 24 | $9.1M | $-40.5M | ||
| Q2 24 | $8.7M | $-45.5M | ||
| Q1 24 | $5.3M | $-55.5M |
自由现金流FDBCRGNX
| Q4 25 | $24.8M | $-52.8M | ||
| Q3 25 | $2.2M | $-56.5M | ||
| Q2 25 | $6.9M | $-49.7M | ||
| Q1 25 | $11.5M | $32.6M | ||
| Q4 24 | $24.9M | $-32.7M | ||
| Q3 24 | $7.8M | $-40.9M | ||
| Q2 24 | $7.2M | $-46.0M | ||
| Q1 24 | $4.0M | $-56.0M |
自由现金流率FDBCRGNX
| Q4 25 | 101.7% | -174.0% | ||
| Q3 25 | 9.3% | -189.9% | ||
| Q2 25 | 29.6% | -232.8% | ||
| Q1 25 | 52.3% | 36.6% | ||
| Q4 24 | 117.3% | -154.2% | ||
| Q3 24 | 38.1% | -168.9% | ||
| Q2 24 | 36.6% | -206.2% | ||
| Q1 24 | 20.7% | -358.5% |
资本支出强度FDBCRGNX
| Q4 25 | 71.9% | 1.7% | ||
| Q3 25 | 26.5% | 1.7% | ||
| Q2 25 | 24.4% | 1.8% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 22.0% | 5.1% | ||
| Q3 24 | 6.3% | 1.3% | ||
| Q2 24 | 7.5% | 2.1% | ||
| Q1 24 | 6.7% | 3.6% |
现金转化率FDBCRGNX
| Q4 25 | 5.34× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.82× | — | ||
| Q1 25 | 1.95× | 5.53× | ||
| Q4 24 | 5.07× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 1.76× | — | ||
| Q1 24 | 1.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FDBC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
